Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL852495 | 1.00 | KMT2A (0.62) | KMT2AALDH1A1MEN1LMNATSHR | |
| Hydrochloric Acid SCHEMBL1143309 | 1.00 | KMT2A (0.62) | KMT2AALDH1A1MEN1LMNATSHR | |
| SCHEMBL318460 | 0.98 | KMT2A (0.64) | KMT2AALDH1A1MEN1LMNATSHR | |
| SCHEMBL283419 | 0.98 | KMT2A (0.64) | KMT2AALDH1A1MEN1LMNATSHR | |
| SCHEMBL318862 | 0.98 | KMT2A (0.64) | KMT2AALDH1A1MEN1LMNATSHR | |
| SCHEMBL29841724 | 0.98 | KMT2A (0.64) | KMT2AALDH1A1MEN1LMNATSHR | |
| SCHEMBL7252180 | 0.87 | KMT2A (0.48) | KMT2AALDH1A1TSHRCYP1A2CYP2D6 | |
| SCHEMBL5514179 | 0.87 | KMT2A (0.52) | KMT2AALDH1A1CYP1A2CYP3A4PTGS2 | |
| Cadaverine Tartrate SCHEMBL32662849 | 0.86 | KMT2A (0.51) | KMT2AALDH1A1MEN1LMNATSHR | |
| SCHEMBL27865114 | 0.85 | KMT2A (0.53) | KMT2AALDH1A1MEN1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662204-A2 | TELOMERASE INHIBITOR COMPOUNDS | Geron Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-10-17 | — | — | US | disclosed |
| WO-2024168165-A2 | TELOMERASE INHIBITOR COMPOUNDS | GERON CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2024-06-20 | — | — | US | disclosed |
| CN-112218858-B | 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-06-18 | — | — | CN | disclosed |
| US-11999731-B2 | EGFR dimer disruptors and use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-05-30 | — | — | US | disclosed |
| CN-118026886-A | Synthesis method of various functionalized beta-amino acid esters | 国科大杭州高等研究院 | 2024-05-14 | — | — | CN | disclosed |
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2024-02-20 | — | — | US | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| CN-1659182-A | Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions | ASTRAZENECA AB (SE) | 2005-08-24 | — | — | CN | disclosed |
| CN-1481373-A | 1,5-benzothiazepines compounds and its use as antilipemic agent | — | 2004-03-10 | — | — | CN | disclosed |
| CN-1422256-A | Anti-acid-fast bacterial agents containing pyridonecarboxylic acids as the active ingredent | DAIICHI SEIYAKU CO (JP) | 2003-06-04 | — | — | CN | disclosed |
| EP-1237874-A2 | SELECTIVE NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6436928-B1 | IN COMBINATION WITH A SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SUBSTITUTED CYCLIC UREAS (IMIDAZOLIDINONES); ANTAGONISTS OF TACHYKININ RECEPTORS, IN PARTICULAR AS ANTAGONISTS OF THE NEUROPEPTIDES NEUROKININ-1 RECEPTOR (NK.SUB.1). | SCHERING CORPORATION | 2002-08-20 | — | — | US | disclosed |
| WO-2001044200-A2 | SELECTIVE NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |
| CN-1253554-A | Heterocyclic compounds and their use for inhibiting 'beta'-amyloid peptide | ELAN MEDICINE CO (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0410244-A1 | Leukotriene antagonists | BAYER AG (DE) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905283-B2 | Compounds and compositions for inhibiting the activity of SHP2 | PTPN1, PTPN2, PTPN5 | PTGS1 1519/4885PTGS2 1917/4885SLC6A2 4731/4885 |
| US-20240343713-A1 | TELOMERASE INHIBITOR COMPOUNDS | TERT, POT1, TERF2 | PTGS1 677/4885PTGS2 1915/4885SLC6A2 4872/4885 |
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | PTGS1 543/4885PTGS2 386/4885SLC6A2 127/4885 |
| US-20240174671-A1 | New 2,3-Dihydro-1H-pyrrolo[3,2-b]pyridine Derivatives as Sigma Ligands | SIGMAR1, OPRD1, TMEM97 | PTGS1 497/4885PTGS2 424/4885SLC6A2 495/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | PTGS1 1713/4885PTGS2 1374/4885SLC6A2 4763/4885 |
| US-11999731-B2 | EGFR dimer disruptors and use of the same | EGFR, ERBB2, ERBB4 | PTGS1 3824/4885PTGS2 3721/4885SLC6A2 4877/4885 |
| US-20240199609-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN2, PTPN5 | PTGS1 1519/4885PTGS2 1917/4885SLC6A2 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.